Two Arena Pharmaceuticals researchers will present the latest data on etrasimod and its therapeutic potential in treating autoimmune diseases such as ulcerative colitis at a summit in Barcelona on Friday, the company has announced.
Dr. Scott Lee and Prof. Tanja Kühbacher will offer three presentations on etrasimod, which Arena describes as an " oral, next generation, selective S1P receptor modulator," during the three-day 12th Congress of European Crohn's and Colitis Organization (ECCO) - Inflammatory Bowel Diseases 2017.
Lee and Kühbacher will begin with a presentation in the conference venue’s poster exhibition area on the safety and lymphocyte-lowering properties of etrasimod. Later in the day, Lee will discuss the immunomodulatory effects of etrasimod in a digital oral presentation, then Kühbacher will deliver a second digital oral presentation on the pharmacology and safety of etrasimod.
Arena Pharmaceuticals focuses on the development of innovative, small-molecule drugs. It is headquartered in San Diego, and has clinical facilities and commercial manufacturing operations in Switzerland.
Additional information on the specific presentations is available in the Journal of Crohn's and Colitis, Volume 11, Issue Supplement 1.
